Browse the evidence

The addition of a self-monitoring wearable device did not provide additional benefit for weight loss compared to the intervention workbook alone.

The use of wearable devices may not be necessary for weight loss interventions focused on eating behaviors.

Strategic dietary modulation, particularly a marked reduction in LA intake, may restore mitochondrial redox homeostasis and improve metabolic health.

Reducing linoleic acid in the diet could enhance mitochondrial function and overall metabolic health.

Subgroup analyses showed no effect on results when stratifying studies according to combined SJ + MJ versus MJ training alone.

Combining SJ and MJ exercises does not show a distinct advantage in hypertrophy outcomes.

Current lipid-lowering drugs are being questioned for their usefulness and may be harmful.

Practitioners should critically evaluate the use of lipid-lowering drugs in their practice.

There was a 100-fold increase in the prescription period prevalence of weight loss agents in the active component from their initial authorization date.

Practitioners should be aware of the significant increase in weight loss medication prescriptions among military personnel.

Service members in health care occupations and the Navy had higher prevalence of weight loss medication prescriptions compared to other service branches and occupations.

This information can inform targeted strategies for weight loss medication distribution within the military.

The number of bariatric surgeries in Germany is significantly increasing.

Healthcare providers should be aware of the growing demand for bariatric surgery.

GLP-1ra users have similar postoperative outcomes following body contouring surgery compared to non-GLP-1ra controls.

Practitioners can consider GLP-1ra use as not adversely affecting postoperative outcomes in body contouring surgeries.

Postoperative cellulitis occurred less frequently among GLP-1ra users in matched cohorts.

GLP-1ra use may be associated with a lower risk of postoperative cellulitis.

Wound dehiscence is more prevalent among patients taking GLP-1ras for diabetes compared to those using it for weight loss.

Consideration of the indication for GLP-1ra use may be important in assessing surgical risk.

One-year discontinuation rates for GLP-1 receptor agonists can be as high as 74% in real-world studies.

Healthcare providers should be aware of the high discontinuation rates of GLP-1 RAs in real-world settings.

The percent kilocalories from carbohydrate was higher in the omnivorous group compared to the vegan group.

Omnivorous diets may provide a higher carbohydrate intake compared to vegan diets, which could influence overall energy balance.

Obesity rates are high in high-income countries and are rapidly increasing in low- and middle-income countries.

Public health initiatives should focus on addressing obesity in both high-income and low-income countries.

The global consumption of unhealthy products, such as soft drinks and processed foods, continues to rise.

Efforts to promote healthier eating habits must address the rising consumption of unhealthy products.

The expansion of multinational food and beverage companies, or ‘Big Food’, is a key factor behind rising obesity rates and unhealthy consumption.

Regulatory measures may be needed to address the influence of 'Big Food' on public health.

Reduction in HbA1c was not significantly different between the high- and low-dose intervention.

Both high and low doses of produce prescriptions may be equally effective for HbA1c reduction.

L-aspartate administration led to a significant reduction in body weight, with decreases of 14.5% in HFC diet mice and 8.5% in HFC diet-induced obese mice.

L-aspartate may be considered as a potential treatment for obesity in similar dietary contexts.

Obesity has reached an epidemic scope in the United States and is a significant public health concern.

Healthcare practitioners should prioritize addressing obesity as a critical health issue.

Plastic surgery in patients with obesity is associated with higher complication rates before and after weight loss.

Surgeons should be aware of the increased risks when operating on obese patients.

The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide is $1845 and $985, respectively.

Healthcare providers should be aware of the cost implications when prescribing these medications.

Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.

Tirzepatide may be considered safe for use in patients at high cardiovascular risk.

The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.

Further research is needed to clarify the cardiovascular benefits of tirzepatide.

Bariatric surgery cannot completely eliminate the possibility of weight regain and inadequate weight loss.

Patients should be informed about the potential for weight regain after surgery.

Changes in lean mass (LM) are not significantly associated with the risk of kidney outcomes (adjusted HR 0.78, 95% CI 0.58-1.06) in participants with overweight/obesity and T2DM.

Practitioners may not need to prioritize lean mass changes for kidney health in T2DM patients.